Streetbeat News

Analyst Ratings

HOWL

Wedbush analyst Robert Driscoll has initiated coverage on Werewolf Therapeutics (NASDAQ:HOWL) with an Outperform rating and a price target of $9.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:12 pm

TOL

Oppenheimer analyst Tyler Batory maintains an Outperform rating on Toll Brothers (NYSE:TOL) and raises the price target from $99 to $110.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:09 pm

SNOW

Oppenheimer analyst Ittai Kidron has reiterated an Outperform rating on Snowflake (NYSE:SNOW) and maintained a $220 price target.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:08 pm

SPLK

Oppenheimer analyst Ittai Kidron has reiterated an Outperform rating on Splunk (NASDAQ:SPLK) and maintained a price target of $115.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:07 pm

FCX

FLT

GLD

Stephen Weiss of Short Hills Capital Partners recommended Freeport-McMoRan Inc. (FCX) which reported better than expected Q2 revenue for 2023. Joseph Terranova of Virtus Investment Partners recommended FLEETCOR Technologies, Inc. (FLT) which also reported better-than-expected Q2 results and issued FY23 revenue guidance above estimates. Liz Young of BNY Mellon Investment Management picked SPDR Gold Shares (GLD).

Portfolio Pulse from Lisa Levin

August 24, 2023 | 1:06 pm

BOWL

Oppenheimer analyst Ian Zaffino has maintained an Outperform rating on Bowlero (NYSE:BOWL) but lowered the price target from $19 to $16.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:05 pm

ADSK

Oppenheimer analyst Ken Wong has reiterated an 'Outperform' rating on Autodesk (NASDAQ:ADSK) and maintained a price target of $250.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:04 pm

ADI

Oppenheimer analyst Rick Schafer has reiterated his 'Outperform' rating on Analog Devices (NASDAQ:ADI) and maintained a price target of $215.

Portfolio Pulse from richadhand@benzinga.com

August 24, 2023 | 1:03 pm

HAIN

Hain Celestial Group Inc reported a 2% YoY decline in Q4 FY23 sales to $447.84 million, beating the analyst consensus. Net sales from North America decreased 5.1% YoY. Adjusted gross margin expanded 325 basis points YoY to 22.7%. The company appointed Lee Boyce as the new CFO, effective September 5, 2023. For FY24, the company expects adjusted net sales growth of 2% to 4% and adjusted EBITDA of $155 million - $165 million.

Portfolio Pulse from Shivani Kumaresan

August 24, 2023 | 1:02 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) has received mostly bullish ratings from 21 analysts over the last quarter, with an average price target of $68.38, indicating a potential upside from the current price of $40.04. However, this average has decreased by 27.91% from the previous average price target of $94.85.

Portfolio Pulse from Benzinga Insights

August 24, 2023 | 1:01 pm